

Media Release

ZURICH, SWITZERLAND – 25 MARCH 2010

The Annual General Meeting of Nobel Biocare approves all proposals of the Board of Directors

Nobel Biocare Holding AG's Annual General Meeting today endorsed all proposals put forward by the Board of Directors.

Among others, the Annual General Meeting approved a dividend of CHF 0.55 gross per registered share of CHF 0.40 nominal value. The dividend will be paid on 1 April 2010 (Ex-dividend day: 29 March 2010; record date: 31 March 2010).

The Board members proposed for reelection were re-elected: Stig Eriksson, Antoine Firmenich, Edgar Fluri, Robert Lilja and Rolf Watter.

Daniela Bosshardt-Hengartner, Dr Raymund Breu, Heino von Prondzynski and Dr Oern Stuge were elected as new Board members. According to the by-laws, all Board members have been elected for a one-year term.

At the first board meeting following the Annual General Meeting, Heino von Prondzynski was elected Chairman of the Board and Rolf Watter was re-elected Vice Chairman of the Board.

KPMG, Zurich, has been re-elected as auditors for the financial year 2010.

Further information is available from:

Media:

Nicolas Weidmann
Senior Vice President Global Communications
Tel: +41 43 211 42 80, +41 79 372 29 81
nicolas.weidmann@nobelbiocare.com

Investors:

Süha Demokan
Head of Investor Relations
Tel: +41 43 211 42 30, +41 79 430 81 46
suha.demokan@nobelbiocare.com

Financial reporting calendar 2010:

| | |
|-------------------------------|------------------------|
| Interim Report 1, 2010 | 28 April 2010 |
| Interim Report 2, 2010 | 11 August 2010 |
| Interim Report 3, 2010 | 3 November 2010 |

Disclaimer

This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.

Nobel Biocare (NOBN, SIX Swiss Exchange) is the world leader in innovative restorative and esthetic dental solutions. As a complete solutions provider Nobel Biocare offers the most comprehensive range of solutions from tooth to root, for single tooth to fully edentulous indications. The solutions portfolio covers dental implants (including the key brands NobelActive™, Brånemark System® and NobelReplace™), individualized prosthetics and equipment (NobelProcera™), guided surgery solutions and biomaterials. Nobel Biocare has approximately 2,250 employees and recorded revenue of EUR 581.4 million in 2009. The company is headquartered in Zurich, Switzerland. Production takes place at seven sites located in Canada, Israel, Japan, Sweden, and the US. Nobel Biocare has 35 direct sales organizations.
